Cost-utility analysis and eligibility of dapagliflozin for patients with heart failure across the whole spectrum of ejection fraction

被引：0

作者：

Kim, E. S. ^{[1
]}

Park, S. K. ^{[2
]}

Youn, J. C. ^{[3
]}

Lee, H. Y. ^{[4
]}

Kim, M. S. ^{[5
]}

Choi, J. O. ^{[6
]}

Kang, S. M. ^{[7
]}

Yoo, B. S. ^{[8
]}

Choi, D. J. ^{[9
]}

Oh, B. H. ^{[10
]}

Baek, S. H. ^{[3
]}

机构：

[1] Korea Adv Inst Sci & Technol, Daejeon, South Korea

[2] Catholic Univ Korea, Coll Pharm, Bucheon, South Korea

[3] Catholic Univ Korea, Div Cardiol, Dept Internal Med, Seoul St Marys Hosp, Seoul, South Korea

[4] Seoul Natl Univ Hosp, Dept Internal Med, Seoul, South Korea

[5] Asan Med Ctr, Dept Internal Med, Seoul, South Korea

[6] Samsung Med Ctr, Dept Internal Med, Seoul, South Korea

[7] Yonsei Univ, Dept Internal Med, Coll Med, Seoul, South Korea

[8] Wonju Severance Christian Hosp, Dept Internal Med, Wonju, South Korea

[9] Seoul Natl Univ, Dept Internal Med, Bundang Hosp, Seongnam, South Korea

[10] Mediplex Sejong Hosp, Dept Internal Med, Incheon, South Korea

来源：

EUROPEAN JOURNAL OF HEART FAILURE | 2023年 / 25卷

基金：

新加坡国家研究基金会;

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：197 / 197

页数：1

共 50 条

[21] Dapagliflozin in patients with heart failure and reduced ejection fraction
Giorgio Colombo
Rosa Casella
Alessia Cazzaniga
Chiara Casiraghi
Internal and Emergency Medicine, 2020, 15 : 515 - 517
[22] Dapagliflozin in patients with heart failure and reduced ejection fraction
Colombo, Giorgio
Casella, Rosa
Cazzaniga, Alessia
Casiraghi, Chiara
INTERNAL AND EMERGENCY MEDICINE, 2020, 15 (03) : 515 - 517
[23] Dapagliflozin for patients with heart failure and reduced ejection fraction
Ferry, Abigail
JAAPA-JOURNAL OF THE AMERICAN ACADEMY OF PHYSICIAN ASSISTANTS, 2022, 35 (09): : 51 - 53
[24] Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
McMurray, J. J. V.
Solomon, S. D.
Inzucchi, S. E.
Kober, L.
Kosiborod, M. N.
Martinez, F. A.
Ponikowski, P.
Sabatine, M. S.
Anand, I. S.
Belohlavek, J.
Bohm, M.
Chiang, C. -E.
Chopra, V. K.
de Boer, R. A.
Desai, A. S.
Diez, M.
Drozdz, J.
Dukat, A.
Ge, J.
Howlett, J. G.
Katova, T.
Kitakaze, M.
Ljungman, C. E. A.
Merkely, B.
Nicolau, J. C.
O'Meara, E.
Petrie, M. C.
Vinh, P. N.
Schou, M.
Tereshchenko, S.
Verma, S.
Held, C.
DeMets, D. L.
Docherty, K. F.
Jhund, P. S.
Bengtsson, O.
Sjostrand, M.
Langkilde, A. -M.
NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (21): : 1995 - 2008
[25] Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
Borghi, Claudio
Cicero, Arrigo F. G.
NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (10): : 972 - 972
[26] SODIUM GLUCOSE COTRANSPORTER-2 INHIBITORS ELIGIBILITY IN PATIENTS WITH HEART FAILURE ACROSS THE SPECTRUM OF EJECTION FRACTION
Ferrari, Ilaria
Monzo, Luca
EUROPEAN HEART JOURNAL SUPPLEMENTS, 2022, 24
[27] Cost-effectiveness of Dapagliflozin for Treatment of Patients With Heart Failure With Reduced Ejection Fraction
Parizo, Justin T.
Goldhaber-Fiebert, Jeremy D.
Salomon, Joshua A.
Khush, Kiran K.
Spertus, John A.
Heidenreich, Paul A.
Sandhu, Alexander T.
JAMA CARDIOLOGY, 2021, 6 (08) : 926 - 935
[28] COST-UTILITY ANALYSIS OF EMPAGLIFLOZIN IN CHRONIC HEART FAILURE WITH REDUCED EJECTION FRACTION: A UK HEALTHCARE SYSTEM PERSPECTIVE
Tan, Y. Z.
Birnie, E.
VALUE IN HEALTH, 2022, 25 (01) : S119 - S119
[29] Cost-utility analysis of add-on vericiguat for the treatment of chronic heart failure with reduced ejection fraction in China
Wang, Lu
Huo, Xuechen
Sun, Haiyan
Liu, Feiyu
Huang, Ruiqin
Zhao, Quan
BMC PUBLIC HEALTH, 2024, 24 (01)
[30] Cost-effectiveness of Dapagliflozin in Heart Failure With Reduced Ejection Fraction
Isaza, Nicolas
Calvachi, Paola
Raber, Inbar
Shen, Changyu
Gavin, Michael C.
Garan, A. Reshad
Bellows, Brandon K.
Kazi, Dhruv S.
CIRCULATION, 2020, 142

← 1 2 3 4 5 →